esophageal squamous cell carcinoma
Stories
-
CSPC Megalith Biopharmaceutical registers Phase III trial of enlonstobart with SYS6010
The trial plans to enroll 585 participants, beginning on December 30, 2026, with a primary completion date of December 30, 2029. It is a randomized, controlled, double-blind, multicenter Phase III study evaluating the efficacy and safety of enlonstobart with or without SYS6010 in participants with pathologically residual esophageal squamous cell carcinoma after complete surgical resection.